vs
Freedom Holding Corp.（FRHC）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Freedom Holding Corp.的1.2倍（$772.1M vs $628.6M），Revvity净利率更高（12.7% vs 12.1%，领先0.6%），Revvity同比增速更快（5.9% vs -4.1%），Freedom Holding Corp.自由现金流更多（$651.7M vs $161.8M），过去两年Freedom Holding Corp.的营收复合增速更高（16.3% vs 9.0%）
Freedom Holding Corp.是在美国内华达州注册的投资集团，业务覆盖零售证券经纪交易、资产管理、资本市场服务、投研咨询、投行承销、抵押贷款、保险、银行及其他消费金融服务，核心布局美股、欧洲及以哈萨克斯坦为核心的中亚市场。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
FRHC vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.2倍
$628.6M
营收增速更快
RVTY
高出9.9%
-4.1%
净利率更高
RVTY
高出0.6%
12.1%
自由现金流更多
FRHC
多$489.9M
$161.8M
两年增速更快
FRHC
近两年复合增速
9.0%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $628.6M | $772.1M |
| 净利润 | $76.2M | $98.4M |
| 毛利率 | 96.0% | — |
| 营业利润率 | 14.9% | 14.5% |
| 净利率 | 12.1% | 12.7% |
| 营收同比 | -4.1% | 5.9% |
| 净利润同比 | -2.6% | 3.9% |
| 每股收益（稀释后） | $1.25 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FRHCRVTY
| Q4 25 | $628.6M | $772.1M | ||
| Q3 25 | $526.1M | $698.9M | ||
| Q2 25 | $533.4M | $720.3M | ||
| Q1 25 | $363.7M | $664.8M | ||
| Q4 24 | $655.2M | $729.4M | ||
| Q3 24 | $580.9M | $684.0M | ||
| Q2 24 | $450.7M | $691.7M | ||
| Q1 24 | $464.7M | $649.9M |
净利润FRHCRVTY
| Q4 25 | $76.2M | $98.4M | ||
| Q3 25 | $38.7M | $46.7M | ||
| Q2 25 | $30.4M | $53.9M | ||
| Q1 25 | $-142.7M | $42.2M | ||
| Q4 24 | $78.3M | $94.6M | ||
| Q3 24 | $114.7M | $94.4M | ||
| Q2 24 | $34.4M | $55.4M | ||
| Q1 24 | $95.2M | $26.0M |
毛利率FRHCRVTY
| Q4 25 | 96.0% | — | ||
| Q3 25 | 97.1% | 53.6% | ||
| Q2 25 | 97.4% | 54.5% | ||
| Q1 25 | 96.6% | 56.5% | ||
| Q4 24 | 98.6% | — | ||
| Q3 24 | 99.1% | 56.3% | ||
| Q2 24 | 99.0% | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率FRHCRVTY
| Q4 25 | 14.9% | 14.5% | ||
| Q3 25 | 11.5% | 11.7% | ||
| Q2 25 | 7.6% | 12.6% | ||
| Q1 25 | -42.7% | 10.9% | ||
| Q4 24 | 15.0% | 16.3% | ||
| Q3 24 | 22.1% | 14.3% | ||
| Q2 24 | 9.2% | 12.4% | ||
| Q1 24 | 22.5% | 6.8% |
净利率FRHCRVTY
| Q4 25 | 12.1% | 12.7% | ||
| Q3 25 | 7.4% | 6.7% | ||
| Q2 25 | 5.7% | 7.5% | ||
| Q1 25 | -39.2% | 6.4% | ||
| Q4 24 | 11.9% | 13.0% | ||
| Q3 24 | 19.7% | 13.8% | ||
| Q2 24 | 7.6% | 8.0% | ||
| Q1 24 | 20.5% | 4.0% |
每股收益（稀释后）FRHCRVTY
| Q4 25 | $1.25 | $0.86 | ||
| Q3 25 | $0.63 | $0.40 | ||
| Q2 25 | $0.50 | $0.46 | ||
| Q1 25 | $-2.35 | $0.35 | ||
| Q4 24 | $1.29 | $0.77 | ||
| Q3 24 | $1.89 | $0.77 | ||
| Q2 24 | $0.57 | $0.45 | ||
| Q1 24 | $1.60 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $869.2M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.4B | $7.3B |
| 总资产 | $12.4B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资FRHCRVTY
| Q4 25 | $869.2M | $919.9M | ||
| Q3 25 | $636.0M | $931.4M | ||
| Q2 25 | $567.9M | $991.8M | ||
| Q1 25 | $837.3M | $1.1B | ||
| Q4 24 | $577.9M | $1.2B | ||
| Q3 24 | $569.2M | $1.2B | ||
| Q2 24 | $718.7M | $2.0B | ||
| Q1 24 | $545.1M | $1.7B |
股东权益FRHCRVTY
| Q4 25 | $1.4B | $7.3B | ||
| Q3 25 | $1.2B | $7.4B | ||
| Q2 25 | $1.2B | $7.6B | ||
| Q1 25 | $1.2B | $7.6B | ||
| Q4 24 | $1.3B | $7.7B | ||
| Q3 24 | $1.3B | $7.9B | ||
| Q2 24 | $1.1B | $7.9B | ||
| Q1 24 | $1.2B | $7.8B |
总资产FRHCRVTY
| Q4 25 | $12.4B | $12.2B | ||
| Q3 25 | $10.3B | $12.1B | ||
| Q2 25 | $9.7B | $12.4B | ||
| Q1 25 | $9.9B | $12.4B | ||
| Q4 24 | $9.1B | $12.4B | ||
| Q3 24 | $8.8B | $12.8B | ||
| Q2 24 | $8.5B | $13.4B | ||
| Q1 24 | $8.3B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $717.8M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $651.7M | $161.8M |
| 自由现金流率自由现金流/营收 | 103.7% | 21.0% |
| 资本支出强度资本支出/营收 | 10.5% | 2.6% |
| 现金转化率经营现金流/净利润 | 9.42× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流FRHCRVTY
| Q4 25 | $717.8M | $182.0M | ||
| Q3 25 | $535.3M | $138.5M | ||
| Q2 25 | $480.8M | $134.3M | ||
| Q1 25 | $1.3B | $128.2M | ||
| Q4 24 | $-72.8M | $174.2M | ||
| Q3 24 | $-438.0M | $147.9M | ||
| Q2 24 | $854.1M | $158.6M | ||
| Q1 24 | $309.0M | $147.6M |
自由现金流FRHCRVTY
| Q4 25 | $651.7M | $161.8M | ||
| Q3 25 | $456.4M | $120.0M | ||
| Q2 25 | $450.0M | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | $-92.7M | $149.8M | ||
| Q3 24 | $-447.5M | $125.6M | ||
| Q2 24 | $829.9M | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率FRHCRVTY
| Q4 25 | 103.7% | 21.0% | ||
| Q3 25 | 86.7% | 17.2% | ||
| Q2 25 | 84.4% | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | -14.1% | 20.5% | ||
| Q3 24 | -77.0% | 18.4% | ||
| Q2 24 | 184.1% | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度FRHCRVTY
| Q4 25 | 10.5% | 2.6% | ||
| Q3 25 | 15.0% | 2.6% | ||
| Q2 25 | 5.8% | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | 3.0% | 3.4% | ||
| Q3 24 | 1.6% | 3.3% | ||
| Q2 24 | 5.4% | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率FRHCRVTY
| Q4 25 | 9.42× | 1.85× | ||
| Q3 25 | 13.82× | 2.97× | ||
| Q2 25 | 15.82× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | -0.93× | 1.84× | ||
| Q3 24 | -3.82× | 1.57× | ||
| Q2 24 | 24.83× | 2.87× | ||
| Q1 24 | 3.24× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FRHC
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
